Letztes Feedback

Meta





 

Avanir Pharmaceuticals (AVNR) Upgraded, Marchex (MCHX) Solid Numbers, AstraZeneca (AZN) Spurns Takeo

http://pennyomega.com/img/penny_omega_logo.jpg

chartstockalert

http://pennyomega.com/img/avnr.jpg Avanir Pharmaceuticals, Inc. (AVNR)

AVNR was upgraded from Neutral to Buy and its price target raised from $5.00 to $10.00 per share by brokerage firm Mizuho

A couple of days ago, AVNR reported that the U.S. District Court for the District of Delaware has ruled in favor of the company in its patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications for generic versions of NUEDEXTA(R) (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect.

The ruling protects AVNR's NUEDEXTA patents through 2026, and prevents Par or Impax from bringing a biosimilar to market.

Pseudobulbar affect (PBA) is a neurologic condition characterized by emotional outbursts that are often contrary or exaggerated to the patient’s inner mood state, causing them to laugh or cry uncontrollably. As a result, many of those afflicted with PBA show significant impairment on standard measures of health status, and disruption in occupational and social function, often leading to social isolation.

PBA can occur in stroke survivors or people with other neurologic conditions such as dementia, multiple sclerosis, Lou Gehrig’s disease (ALS) or traumatic brain injury. It is thought to affect more than 1 million people in the U.S.

According to AVNR, new data from the Phase III STAR Trial showed that NUEDEXTA may provide early PBA symptomatic remission. Throughout the trial, sustained episode remission rates in patients treated with NUEDEXTA were significantly higher compared to placebo.

AVNR's NUEDEXTA is the only medication specifically designed and FDA-approved to treat PBA.

http://pennyomega.com/img/avnrch.png

AVNR is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

More about Avanir Pharmaceuticals, Inc. (AVNR) at www.avanir.com.

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

The company is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 505th community website in the U.S., associated with 2047 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada

http://pennyomega.com/img/crwemay2.jpg

CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.

http://pennyomega.com/img/roxzu.jpg CRWE‘s local and national coupon distribution application “Roxzu” (www.roxzu.com) is in its product development stage and is currently online being test marketed for the Las Vegas, Nevada region. Roxzu’s restaurant dining app will also features live dining and restaurant deals.

After testing and review, the application is expected to be integrated in all the geo community CRWE-PR network sites by the end of the 2Q of 2014.

CRWE has plans to expand the application to include auto repairs, realtors, bars, movie theaters, retailers, golf courses, auto dealerships and any other variety of businesses existing within a community.

http://pennyomega.com/img/crwe_medical_marijuana.jpg The CRWE Network, based on the momentum the industry has taken in positioning itself for additional grow in the future, is in the process of building an online medical marijuana informational and directory search platform (www.medicalmarijuana.crwe-pr.com). The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com or the CRWE Network at www.CRWE-PR.com

**

http://pennyomega.com/img/mchx.jpg Marchex, Inc. (MCHX)

For the first quarter 2014, MCHX posted GAAP revenue of $50.5 million, compared to $34.7 million in the same period the prior year, GAAP net income from continuing operations of $846,000, versus $116,000 for the first quarter of 2013, and GAAP net income from continuing operations attributable to common stockholders per diluted share of $0.02, compared to $0.00 in the first quarter ended March 31, 2013.

http://pennyomega.com/img/mchsch.png

MCHX is a mobile advertising technology company. It provides a suite of products and services for businesses that depend on consumer phone calls to drive sales. MCHX’s mobile advertising platform delivers new customer phone calls to businesses, while its technology analyzes the data in these calls to help maximize ad campaign results.

More about Marchex, Inc. (MCHX) at www.marchex.com

**

http://pennyomega.com/img/azn.jpg AstraZeneca PLC (AZN)

The board of directors of AZN rejected Pfizer's $106 billion takeover bid just hours after it was levelled, describing it as inadequate.

Pfizer offered 50 pounds ($84.47) a share in cash and stock. The offer was a 7.3 increase on a previous bid of $100 billion..

http://pennyomega.com/img/aznch.png

AZN is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

More about AstraZeneca PLC (AZN) at www.astrazeneca.com.

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

2.5.14 15:28, kommentieren

Werbung


Theravance (THRX) Positive Results from Chronic Pain Syndrome Study, Alexza Pharmaceuticals (ALXA) A

http://pennyomega.com/img/penny_omega_logo.jpg

chartstockalert

http://pennyomega.com/img/thrx.jpg Theravance Inc. (THRX)

Fibromyalgia has been estimated to affect approximately 5 million individuals in the United States. It is the most common musculoskeletal condition after osteoarthritis. Still, it is often misdiagnosed and misunderstood. Its characteristics include widespread muscle and joint pain and fatigue, as well as other symptoms. Fibromyalgia can lead to depression and social isolation.

Although fibromyalgia is often considered an arthritis-related condition, it is not truly a form of arthritis (a disease of the joints) because it does not cause inflammation or damage to the joints, muscles, or other tissues. Like arthritis, however, fibromyalgia can cause significant pain and fatigue, and it can interfere with a person’s ability to carry on daily activities.

THRX reported positive results from a Phase 2 study of TD-9855 in patients with fibromyalgia

TD-9855, discovered by THRX, is an investigational norepinephrine and serotonin reuptake inhibitor for the treatment of central nervous system conditions such as chronic pain and Attention-Deficit/Hyperactivity Disorder.

The study demonstrated statistically significant and clinically meaningful improvements in the primary and secondary endpoints at the 20 mg dose of TD-9855, which was generally well tolerated and, compared with placebo, significantly improved pain as well as other symptoms commonly associated with fibromyalgia.

http://pennyomega.com/img/thrx.png

THRX is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. It is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain.

More about Theravance Inc. (THRX) at www.theravance.com.

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

http://pennyomega.com/img/roxzu.jpg CRWE‘s local and national coupon distribution application “Roxzu” (www.roxzu.com) is in its product development stage and is currently online being test marketed for the Las Vegas, Nevada region. Roxzu’s restaurant dining app will also features live dining and restaurant deals.

After testing and review, the application is expected to be integrated in all the geo community CRWE-PR network sites by the end of the 2Q of 2014.

CRWE has plans to expand the application to include auto repairs, realtors, bars, movie theaters, retailers, golf courses, auto dealerships and any other variety of businesses existing within a community.

http://pennyomega.com/img/medical_marijuana_crwe_pr.jpg The CRWE Network, based on the momentum the industry has taken in positioning itself for additional grow in the future, is in the process of building an online medical marijuana informational and directory search platform (www.medicalmarijuana.crwe-pr.com). The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 500th community website in the U.S., associated with 2042 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada

http://pennyomega.com/img/crwemay1.jpg

CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com or the CRWE Network at www.CRWE-PR.com

**

http://pennyomega.com/img/alxa.jpg Alexza Pharmaceuticals Inc. (ALXA)

ALXA said that ADASUVE(R) inhalation powder, pre-dispensed (loxapine) is now available in the Nordic countries (Sweden, Norway, Denmark and Finland).

Grupo Ferrer Internacional, S.A. is commercializing ADASUVE in the Nordic countries through a distribution agreement with Medivir AB. Ferrer is ALXA's commercial partner for ADASUVE in the Europe, Latin America and the Commonwealth of Independent States countries.

ALXA and Ferrer estimate that as many as 8 million adults in the EU alone suffer from schizophrenia or bipolar disorder. Agitation is a common symptom for these patients, characterized by feelings of distress, anxiety and loss of control.

ALXA received marketing authorization for ADASUVE from the European Commission in February 2013. ADASUVE is the first inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder authorized for marketing in the EU.

ADASUVE combines ALXA's proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects.

http://pennyomega.com/img/alxa_chart.png

ALXA is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.

More about Alexza Pharmaceuticals Inc. (ALXA) at www.alexza.com

**

http://pennyomega.com/img/flex.jpg Flextronics International Ltd. (FLEX)

Keep a close eye on FLEX. The company reported strong performance on its financial results.

For the fourth quarter fiscal 2014, FLEX posted net sales of $6.7 billion, higher than its previously provided revenue guidance of $5.9 billion to $6.3 billion, and adjusted earnings per diluted share of $0.24, also higher than the company's previously provided guidance of $0.18 to $0.22.

According to its guidance for the first quarter ending June 27, 2014, FLEX expects revenue to be in the range of $6.0 to $6.5 billion and adjusted EPS is expected to be in the range of $0.20 to $0.24 per diluted share.

http://pennyomega.com/img/flexch.png

FLEX is a leading end-to-end supply chain solutions company that delivers design, engineering, manufacturing and logistics services to a range of industries and end-markets, including data networking, telecom, enterprise computing and storage, industrial, capital equipment, appliances, automation, medical, automotive, aerospace and defense, energy, mobile, computing and other electronic product categories

More about Flextronics International Ltd. (FLEX) at www.flextronics.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

1.5.14 10:53, kommentieren

Crown Equity Holdings CRWE-PR Network Reaches 500 Community Websites in U.S and 10 in Canada

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 500th community website in the U.S., associated with 2042 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada

http://pennyomega.com/img/crweapr30.jpg

CRWE Network’s goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums, while providing micro community news, information and business directory content.

http://pennyomega.com/img/roxzu.jpg CRWE‘s local and national coupon distribution application “Roxzu” (www.roxzu.com) is in its product development stage and is currently online being test marketed for the Las Vegas, Nevada region. Roxzu’s restaurant dining app will also features live dining and restaurant deals.

After testing and review, the application is expected to be integrated in all the geo community CRWE-PR network sites by the end of the 2Q of 2014.

CRWE has plans to expand the application to include auto repairs, realtors, bars, movie theaters, retailers, golf courses, auto dealerships and any other variety of businesses existing within a community.

http://pennyomega.com/img/medical_marijuana_crwe_pr.jpg The CRWE Network, based on the momentum the industry has taken in positioning itself for additional grow in the future, is in the process of building an online medical marijuana informational and directory search platform (www.medicalmarijuana.crwe-pr.com). The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com or the CRWE Network at www.CRWE-PR.com

**

Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer at www.crownequityholdings.com/disclaimer.html

1.5.14 06:31, kommentieren

Crown Equity Holdings Inc. Local and National Coupon Online Application Being Developed

http://pennyomega.com/img/crwe_logo.jpg

LAS VEGAS, NV, April 28, 2014 - (CRWE Press Release) - Crown Equity Holdings Inc. (OTCQB: CRWE) announced that its local and national coupon distribution application “Roxzu" (www.roxzu.com) is in its product development stage and is currently online being test marketed for the Las Vegas, Nevada region. Roxzu’s restaurant dining app will also features live dining and restaurant deals.

After testing and review, the application is expected to be integrated in all the geo community CRWE-PR network sites by the end of the 2Q of 2014.

Consumers will be encouraged to use "Roxzu and its Roxzu Live" dining and restaurant coupons in their local communities, which will offer specials and deals of all kinds. The company has plans to expand the application to include auto repairs, realtors, bars, movie theaters, retailers, golf courses, auto dealerships and any other variety of businesses existing within a community.

Visit http://roxzu.com

The CRWE-PR network (http://crwe-pr.com) is a community of websites with local news, information and business directory information and more in over 450 locations across communities within the greater state of California, Northern and Southern Nevada, Wellington in Florida and 10 provinces in Canada."

Visit: http://crwe-pr.com to view locations available.

About Crown Equity Holdings Inc.

Together with its digital network of websites, Crown Equity Holdings Inc., provides and offers advertising branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. The company focuses on the distribution of information for the purpose of bringing together its targeted audience and the advertisers that want to reach them. Its advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. The company launches, invests and manages select businesses, projects and real estate endeavors. For more information regarding Crown Equity Holdings Inc., please visit: http://www.crownequityholdings.com.

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new business opportunities and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission

Contact

Kenneth Bosket, President
702 448-1543

SOURCE: Crown Equity Holdings Inc..

28.4.14 14:44, kommentieren

BioCryst Pharmaceuticals (BCRX) BCX4430, a Hope in the Battle with Ebola, Dejour Energy (DEJ) Black

http://pennyomega.com/img/penny_omega.jpg

chartstockalert

Since its inception in 1969, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has spearheaded research to develop medical solutions—vaccines, drugs, diagnostics, and information—to protect the U.S.' military service members from biological threats. Its specialized capabilities include Biosafety Level 3 and Level 4 laboratories, world-class expertise in the generation of biological aerosols for testing candidate vaccines and therapeutics, and fully accredited animal research facilities.

As the United States continues a new era of civilian biodefense research, it is also clear that USAMRIID plays a critical role in the status of the U.S.' preparedness for biological terrorism and biological warfare. While USAMRIID's primary mission is to protect the warfighter, its research benefits civilians as well.

http://pennyomega.com/img/bcrx.jpg BioCryst Pharmaceuticals, Inc. (BCRX)

Filoviruses, such as Ebola virus and Marburg virus, are extremely virulent. These pathogens are classified as Category A Bioterrorism Agents by the Centers for Disease Control and Prevention. Marburg virus is a member of the family Filoviridae, along with Ravn virus, Ebola virus, Sudan virus and Bundibugyo virus, all of which cause severe viral hemorrhagic fevers in humans.

Ebola virus disease, formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans, characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. Laboratory findings include low white blood cell and platelet counts and elevated liver enzymes.

Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals. Ebola then spreads in the community through human-to-human transmission, with infection resulting from direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and indirect contact with environments contaminated with such fluids.

More than 120 people have died from the latest Ebola outbreak in West Africa. With no cure or vaccine, it is one of the most deadly of viruses, killing between 60% to 90% of those infected.

Health officials do not expect the virus to go global and stress that Ebola is not easy to catch, requiring direct contact with an infected victim’s bodily fluids.

BCRX recently reported the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virulent pathogens responsible for viral hemorrhagic fever diseases.

The Nature online publication, "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430," (http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13027.html) represents the first report of protection of non-human primates from filovirus disease by a small molecule drug, and describes efficacy results generated from an ongoing collaboration between scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and BCRX.

Developed by BCRX, BCX4430 has demonstrated antiviral activity in testing conducted at BCRX Utah State University/NIAID and USAMRIID. BCX4430 has been shown to be active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.

In tests conducted at USAMRIID, BCX4430 protected animals against parenteral exposures to Marburg, Ebola and Rift Valley Fever viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack.

BCX4430, a viral RNA-dependent RNA polymerase (RdRp) inhibitor, is being developed as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BCRX for the development of BCX4430 as a treatment for Marburg virus disease. In 2013, NIAID awarded funding of $7.5 million to BCRX, and total funding of up to $22.0 million, if all contract options are exercised. The goals of this contract are to file investigational new drug (IND) applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.

http://pennyomega.com/img/bcrxapr15.png

BCRX designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians.

More about BioCryst Pharmaceuticals, Inc. (BCRX) at www.BioCryst.com.

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 433th community website in the U.S., associated with 1894 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada

The CRWE Network also is in the process of building an online medical marijuana informational and directory search platform. (http://medicalmarijuana.crwe-pr.com) The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

The addition of having CRWE-PR’s online medical marijuana news, information and directory is based on the momentum the industry has taken in positioning itself for additional grow in the future.

http://crwe-pr.com/wp-content/uploads/2013/12/CRWE_Network.jpg

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

http://pennyomega.com/img/dej.jpg Dejour Energy Inc. (DEJ)

Keep a close eye on DEJ. The company reported that gross daily production at its Woodrush project in NE British Columbia is currently 540 boepd (380 net), an increase of 60% over average gross daily production during the fourth 2013 of 316 boepd (237 net).

Recently, DEJ closed the purchase of certain natural gas producing assets and related processing facilities adjacent to its Woodrush oilfield 120 km. north of Ft. St. John, B.C.

The assets acquired include a 54% working interest in a currently producing Halfway formation well and a 74% working interest in 3 shut-in Halfway natural gas wells. One of those wells has now been reactivated and is producing an additional ~1mmcf/d into DEJ’s sales line at Woodrush.

DEJ is analyzing the best procedure for reactivating the remaining wells. Proven Developed Producing reserve additions are now being calculated.

In 2013, DEJ generated $9.3 million in gross revenues, a 35% increase over 2012, and positive cash flow from operations of $521,000 compared with a cash deficiency from operations of $2.2 million in 2012.

http://pennyomega.com/img/dej_apr15.png

DEJ is an independent oil and natural gas exploration and production company operating projects in North America’s Piceance Basin (approximately 71,500 net acres) and Peace River Arch regions (approximately 17,000 net acres).

More about Dejour Energy Inc. (DEJ) at www.dejour.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

16.4.14 09:18, kommentieren

Zebra Technologies (ZBRA) Strong Numbers Signals, Lannett Company (LCI) FDA Green Light for Bioequiv

http://pennyomega.com/img/penny_omega_logo.jpg

chartstockalert

http://pennyomega.com/img/zbra.jpg Zebra Technologies Corp. (ZBRA)

ZBRA reported that it expects to report sales for the first quarter of 2014 in the range of $287,000,000 to $289,000,000, or 21% over the $236,937,000 in sales reported for the same period the prior year, while ZBRA's earnings are expected in a range of $0.79 to $0.82 per share, up approximately 74% from $0.46 per share for the first quarter of 2013.

ZBRA also announced that it will acquire Motorola's Enterprise business for $3.45 billion in an all-cash transaction.

http://pennyomega.com/img/zbra_chart.png

ZBRA offers technologies that give a virtual voice to an organization's assets, people and transactions, enabling organizations to unlock greater business value.

More about Zebra Technologies Corp. (ZBRA) at www.Zebra.com.

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 431th community website in the U.S., associated with 1887 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada

The CRWE Network also is in the process of building an online medical marijuana informational and directory search platform. (http://medicalmarijuana.crwe-pr.com) The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

The addition of having CRWE-PR’s online medical marijuana news, information and directory is based on the momentum the industry has taken in positioning itself for additional grow in the future.

http://pennyomega.com/img/crweapr15.jpg

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

http://pennyomega.com/img/lci.jpg Lannett Company, Inc. (LCI)

LCI reported that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application for Diazepam Oral Solution (Concentrate), 5 mg/mL, a Schedule C-IV controlled drug.

Diazepam Oral Solution (Concentrate), 5 mg/mL, is therapeutically equivalent to the reference listed drug, Diazepam Intensol Oral Solution (Concentrate), 5 mg/mL, of Roxane Laboratories, Inc.

http://pennyomega.com/img/lciabr15.png

LCI develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

More about Lannett Company, Inc. (LCI) at www.lannett.com.

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

15.4.14 15:33, kommentieren

Lexicon (LXRX) Top-line Results In Type 1 Diabetes Clinical Trial, Crown Equity Holdings Adds Medica

http://pennyomega.com/img/penny_omega_logo.jpg

chartstockalert

http://pennyomega.com/img/lxrx.jpg Lexicon Pharmaceuticals, Inc. (LXRX)

Diabetes is a disorder of metabolism—the way the body uses digested food for growth and energy. Most of the food people eat is broken down into glucose, the form of sugar in the blood.

Glucose is vital to your health because it's an important source of energy for the cells that make up your muscles and tissues. It's also your brain's main source of fuel.

The three main types of diabetes are: type 1 diabetes, type 2 diabetes and gestational diabetes.

Type 1 diabetes is a serious condition affecting more than one million people in the United States, both children and adults. Type 1 diabetes is an autoimmune disease in which a person's pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas. A person who has type 1 diabetes must take insulin daily to live.

Symptoms of type 1 diabetes usually develop over a short period, although beta cell destruction can begin years earlier, and may include increased thirst and urination, constant hunger, weight loss, blurred vision, and extreme fatigue. If not diagnosed and treated with insulin, a person with type 1 diabetes can lapse into a life-threatening diabetic coma, also known as diabetic ketoacidosis.

LXRX reported positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control.

According to LXRX, the results from this study provide a clear demonstration of proof-of-concept of LX4211 as an oral, investigational new drug for type 1 diabetes complementing insulin therapy, and the magnitude of improved glycemic control by several measures, including HbA1c in only four weeks, and lower insulin requirements are highly encouraging and support the progression of LX4211 into late-stage development for type 1 diabetes

LXRX's LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through two insulin-independent mechanisms of action.

http://pennyomega.com/img/lxrx_chart.png

LXRX is focused on developing breakthrough treatments for human disease. LXRX has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by its research team.

More about Lexicon Pharmaceuticals, Inc. (LXRX) at www.lexpharma.com.

**

http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)

CRWE is currently developing its CRWE Network (CRWE-PR.com), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada.

Update: The CRWE Network, which business model is based on selling advertising to local businesses, has reached the 420th community website in the U.S., associated with 1870 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, Wellington in Florida and 9 provinces in Canada

The CRWE network also is in the process of building an online medical marijuana informational and directory search platform. (http://medicalmarijuana.crwe-pr.com) The purpose of the site is to connect people with information in reference to the industry and patients to a network of physicians, dispensaries and more in reference to States with approved Medical Marijuana usage.

The addition of having CRWE-PR’s online medical marijuana news, information and directory is based on the momentum the industry has taken in positioning itself for additional grow in the future.

http://crwe-pr.com/wp-content/uploads/2013/12/CRWE_Network.jpg

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

http://pennyomega.com/img/bebe.jpg Bebe Stores, Inc. (BEBE)

BEBE was upgraded from Neutral to Buy with a price target of $7.50 by brokerage firm Janney Montgomery Scott

http://pennyomega.com/img/bebe_chart.png

BEBE is a global specialty retailer, which designs, develops and produces a distinctive line of contemporary women’s apparel and accessories under the bebe, BEBE SPORT, bbsp and 2b bebe brand names.

More about Bebe Stores, Inc. (BEBE) at www.bebe.com

**

http://pennyomega.com/img/adxs.jpg Advaxis, Inc. (ADXS)

ADXS said that the Japan Patent Office issued to the company two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to ADXS' proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.

One of the patent applications allowed by the Japan Patent Office covers ADXS' immunotherapy treatments targeting factors that are essential for tumors or metastases to form new blood vessels (angiogenesis) or that are expressed by tumor blood vessels. The second patent applicationcovers the form of a recombinant attenuated auxotrophic Listeria having specific mutations conferring attenuation along with plasmid that complements the genomic mutation and also expresses a protein antigen fused to highly immunogenic Listeria peptides or other strongly immunogenic pathogen-associated peptide sequences.

It has already been established that attacking a tumor's blood supply is an important strategy in preventing the tumor from growing and spreading and the addition of these two patents in Japan further allows ADXS to protect key elements of its proprietary cancer immunotherapies

http://pennyomega.com/img/adxsch.png

ADXS' immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses.

ADXS is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies.

More about Advaxis, Inc. (ADXS) at www.advaxis.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer

14.4.14 16:18, kommentieren